Table 2. Baseline characteristics of the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS).
| Control | Ischemic stroke | LVD | SVD | CE | Cryptogenic stroke | |
| (n = 600) | (n = 600) | (n = 73) | (n = 124) | (n = 98) | (n = 162) | |
| Median age, yr (IQR) | 58 (51–64) | 58 (51–64) | 60 (57–64) | 59 (54–64) | 61 (53–65) | 56 (48–61) |
| Male, n (%) | 385 (64) | 385 (64) | 54 (74) | 77 (62) | 66 (67) | 95 (59) |
| Hypertension, n (%) | 224 (37) | 354 (59) | 44 (63) | 89 (72) | 50 (52) | 87 (54) |
| Diabetes, n (%) | 33 (5) | 114 (19) | 25 (34) | 26 (21) | 19 (19) | 23 (14) |
| Hyperlipidemia, n (%) | 403 (67) | 413 (69) | 53 (81) | 77 (71) | 73 (82) | 107 (71) |
| Current smoking, n (%) | 109 (18) | 233 (39) | 39 (54) | 54 (43) | 34 (35) | 60 (37) |
| NIHSS ac, m (IQR) | N/A | 2.9 (1.6–7.2) | 3.3 (1.2–11.5) | 2.2 (1.3–4.1) | 3.8 (1.2–11.1) | 2.5 (1.2–6.4) |
| NIHSS 3m, m (IQR) | N/A | 0.7 (0.7–2.5) | 1.6 (0.7–3.3) | 0.7 (0.7–2.0) | 1.2 (0.7–3.3) | 0.7 (0.7–2.5) |
| ΔNIHSS, m (IQR) | N/A | −1.3 (−3.9 to 0) | −1.3 (−3.0 to 0) | −0.8 (−2.6 to 0) | −1.7 (−4.7 to 0) | −1.3 (−4.1 to 0) |
| rs6265, MAF | 0.19 | 0.18 | 0.17 | 0.19 | 0.24 | 0.14 |
| rs11030107, MAF | 0.27 | 0.24 | 0.24 | 0.25 | 0.25 | 0.26 |
| rs11030119, MAF | 0.31 | 0.29 | 0.31 | 0.30 | 0.27 | 0.30 |
| rs2049046, MAF | 0.44 | 0.47 | 0.47 | 0.45 | 0.42 | 0.51 |
Data are shown as median (m) and interquartile range (IQR), number (n) and percentage, or minor allele frequency (MAF). LVD, large vessel disease; SVD, small vessel disease; CE, cardioembolic stroke; NIHSS ac, initial stroke severity during the acute phase; NIHSS 3m, stroke severity after 3 months; ΔNIHSS, recovery defined as change in NIHSS from acute to 3-month post-stroke, with a negative value indicating clinical improvement.